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Background: Whether children with chromosomal disorders of growth and puberty are 
affected by secular trends (STs) as observed in the general population remains unan-
swered, but this question has relevance for expectations of spontaneous development 
and treatment responses.
Objectives: The aim of the study was to evaluate STs in birth parameters, growth, and 
pubertal development in girls with Turner syndrome (TS).
study design: Retrospective analysis of KIGS data (Pfizer International Growth 
Database). We included all TS patients who entered KIGS between 1987 and 2012 and 
were born from 1975 to 2004, who were prepubertal and growth treatment naïve at first 
entry (total number: 7,219). Pretreatment height and ages at the start of treatment were 
compared across 5-year birth year groups, with subgroup analyses stratified by induced 
or spontaneous puberty start.
results: We observed significant STs across the birth year groups for birth weight [+0.18 
SD score (SDS), p <  0.001], pretreatment height at mean age 8  years (+0.73 SDS, 
p < 0.001), height at the start of growth hormone (GH) therapy (+0.38 SDS, p < 0.001) 
and start of puberty (+0.42 SDS, p < 0.001). Spontaneous puberty onset increased from 
15 to 30% (p < 0.001). Mean age at the start of GH treatment decreased from 10.8 to 
7.4 years (−3.4 years; p < 0.001), and substantial declines were seen in ages at onset of 
spontaneous and induced puberty (−2.0 years; p < 0.001) and menarche (−2.1 years; 
p < 0.001).
conclusion: Environmental changes leading to increased height and earlier and also 
more common, spontaneous puberty are applicable in TS as in normal girls. In addition, 
greater awareness for TS may underlie trends to earlier start of GH therapy and induction 
of puberty at a more physiological age.
Keywords: Turner syndrome, height, growth, birth weight, birth length, puberty, secular trend
Abbreviations: BL, birth length; BMI, body mass index; BW, birth weight; GH, growth hormone; ST, secular trend; TS, Turner 
syndrome.
TaBle 1 | Patients characteristics (total cohort).
Variables N Median P10 P90 Mean sD
Birth weight SD score (SDS) 6,372 −1.05 −2.52 0.39 −1.05 1.19
Birth length SDS 4,500 −0.87 −2.52 0.82 −0.85 1.41
Midparental Height SDS 6,571 −0.49 −2.01 1.00 −0.50 1.17
Height SDS at age 8 years 
(Prader)
1,091 −2.19 −3.23 −1.21 −2.20 0.81
Height SDS at age 8 years 
(Ranke)
1,091 0.13 −1.15 1.34 0.12 1.02
Age at the start of growth 
hormone (GH) tx
7,219 9.60 4.41 13.97 9.35 3.63
Height SDS at the start of  
GH tx (Prader)
7,219 −3.22 −4.55 −2.03 −3.26 1.06
Height SDS at the start of  
GH tx (Ranke)
7,132 0.19 −1.17 1.54 0.19 1.12
Weight SDS 7,219 −1.44 −3.06 0.30 −1.43 1.34
Body mass index SDS 7,218 0.31 −1.09 1.87 0.34 1.17
GH dose (mg/kg/week) 7,219 0.31 0.18 0.38 0.30 0.09
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inTrODUcTiOn
Secular trends (STs) in birth parameters (1–3), growth (4, 5), and 
timing of puberty (6–8) are observed in normal populations in 
various settings. Changes in nutrition, better access to health care, 
and other environmental factors have been implicated as causa-
tive factors for these changes (4). Whether STs that affect normal 
populations also modulate growth and puberty of children with 
genetic or chromosomal disturbances that inherently affect 
growth and puberty remains unanswered.
Turner syndrome (TS) is caused by structural abnormalities 
in or complete loss of an X chromosome. It affects approximately 
1 in 2,500 live-born female girls. The clinical phenotype of TS 
varies substantially, but in the majority of subjects includes 
short stature and ovarian failure, leading to hypogonadism and 
infertility (9).
In subjects with TS, haploinsufficiency of the SHOX gene has 
been proposed as an important cause of the growth phenotype 
in TS, since patients with heterozygous mutations in SHOX 
exhibit Leri-Weill syndrome, a bone dysplasia associated with 
short stature (10), whereas homozygous mutations with loss 
of both SHOX gene copies lead to a rare severe osteodysplasia 
(11). However, haploinsufficiency for the SHOX gene does 
not fully explain the growth phenotype and its variation in TS 
subjects. Probably, other factors such as estrogen deficiency 
(12), loss of additional X-chromosomal genes, or more general 
aneuploidy effects might be implicated in TS-associated short 
stature (13).
Although the majority of girls with TS have normal birth 
parameters, the frequency of TS in newborns with low birth 
weight (BW) and length is higher than expected (14, 15). This 
has been explained in part by loss or altered expression of 
X-chromosomal genes that are involved in fetal growth (16). 
Data analyzing the evolution of birth parameters in a sufficiently 
sized TS cohort over time to identify a ST in BW and length are 
lacking.
Girls with TS frequently exhibit delayed or absent pubertal 
development due to early ovarian failure. The exact molecular 
mechanisms leading to ovarian dysfunction in TS remain obscure. 
In a minority of patients (5–20%), puberty starts spontaneously 
and may even lead to spontaneous menarche in few subjects 
(17, 18). This seems to occur more frequently in subjects with a 
higher degree of mosaicism. As for auxological parameters, data 
on the presence or absence of an ST on spontaneous or induced 
puberty in TS are not available.
OBJecTiVes
To assess STs on birth parameters, spontaneous growth and 
pubertal development in patients with TS and to evaluate whether 
clinical management of girls with TS has changed over time.
Patients
The patients studied had received recombinant growth hor-
mone (GH, Genotropin®, Pfizer Inc.) as part of the pharma-
coepidemiologic survey known as KIGS® (Pfizer International 
Growth Database). KIGS was established in 1987 as a 
worldwide observational registry to monitor outcomes and safety 
of Genotropin (somatropin, Pfizer Inc., New York, NY, USA) 
treatment in children with short stature. The KIGS survey was 
conducted in accordance with the Declaration of Helsinki (19).
As of June 2012, TS patients who entered the KIGS registry 
between 1987 and 2012 were included (total number: 7,219). 
Only patients who were at the prepubertal stage and naïve to any 
growth treatment at first entry were included. Birth years ranged 
from 1975 to 2004. The diagnosis of TS was made according to 
standard clinical practice and was confirmed by karyotype by 
the treating physicians. Patients’ characteristics are depicted in 
Table 1.
aims and hypotheses
The main objective of this study was to assess STs on birth 
parameters, spontaneous growth, and pubertal development in 
patients with TS and to evaluate whether clinical management 
of girls with TS had changed over time. We had the following 
hypotheses:
 – There is a positive ST for birth parameters.
 – There is a positive ST for height before initiation of GH treatment.
 – There is a positive ST for onset of puberty in the total TS 
cohort.
In order to address the outlined objectives, we analyzed data 
from three subcohorts derived from the KIGS database.
To assess STs, KIGS data on BW, birth length (BL), height SD 
score (SDS) at 8  years of age (chronological age 7.0–9.0  years) 
before initiation of any treatment, height SDS, and age at the 
start of GH therapy and at the start of puberty were analyzed in 
time intervals which were defined by year of birth (before 1980, 
1980–1984, 1985–1989; 1990–1994; 1995–1999; and 2000–2004).
Methods
Cohort 1a was used to assess trends both in pretreatment height 
and in the age at the start of GH therapy. Inclusion required suf-
ficient pretreatment data without exposure to therapies affecting 
growth (GH, oxandrolone, and sex steroids). To assess trends in 
TaBle 2 | Secular trends on birth parameters and growth (mean ± SD).
Birth year Before 1980 1980–1984 1985–1989 1990–1994 1995–1999 2000–2004 p-Value
at birth
N = [birth weight(BW)/birth length (BL)] 769/492 1163/777 1552/1123 1409/992 948/688 531/428
BW SD score (SDS) −1.18 ± 1.18 −1.11 ± 1.20 −1.04 ± 1.20 −1.00 ± 1.18 −0.99 ± 1.17 −1.00 ± 1.16 <0.001
BL SDS –0.97 ± 1.42 −0.83 ± 1.38 −0.84 ± 1.41 −0.78 ± 1.38 −0.78 ± 1.53 −1.00 ± 1.37 <0.001
Midparental height SDS −0.82 ± 1.17 −0.65 ± 1.17 −0.44 ± 1.14 −0.44 ± 1.16 −0.37 ± 1.17 −0.29 ± 1.16 <0.001
at ghT start (cohort #1a)
N =  855 1306 1729 1621 1107 601
Age (years) 12.68 ± 2.01 10.85 ± 2.93 9.70 ± 3.33 8.83 ± 3.44 7.43 ± 3.24 5.26 ± 2.39 <0.001
Height SDS (Prader) −3.72 ± 1.05 −3.42 ± 1.02 −3.28 ± 0.95 −3.15 ± 0.98 −3.04 ± 1.22 −2.97 ± 1.13 <0.001
Height SDS (Ranke) −0.05 ± 01.12 0.10 ± 1.10 0.21 ± 1.05 0.25 ± 1.07 0.30 ± 1.29 0.32 ± 1.08 <0.001
Δ Height − MPH SDS −2.90 ± 1.11 −2.77 ± 1.18 −2.79 ± 1.16 −2.68 ± 1.19 −2.65 ± 1.37 −2.68 ± 1.23 <0.01
Weight SDS −1.59 ± 1.31 −1.47 ± 1.32 −1.35 ± 1.30 −1.33 ± 1.36 −1.40 ± 1.40 −1.65 ± 1.38 NS
Body mass index (BMI) SDS 0.42 ± 1.08 0.37 ± 1.13 0.41 ± 1.16 0.39 ± 1.21 0.28 ± 1.17 −0.04 ± 1.21 NS
at age 8 years (cohort #1b)
N =  18 226 287 280 178 102
Height SDS (Prader) −2.69 ± 0.79 −2.41 ± 0.79 −2.22 ± 0.77 −2.14 ± 0.78 −2.08 ± 0.86 −1.96 ± 0.87 <0.001
Height SDS (Ranke) −0.44 ± 1.01 0.13 ± 1.00 0.10 ± 0.96 0.18 ± 0.98 0.27 ± 1.07 0.39 ± 1.09 <0.001
Δ Height − MPH SDS −2.86 ± 1.06 −2.83 ± 1.11 −2.79 ± 1.16 −2.81 ± 1.14 −2.71 ± 1.12 −2.55 ± 1.32 NS
Weight SDS −1.41 ± 1.32 −1.49 ± 1.15 −1.35 ± 1.20 −1.28 ± 1.24 −1.14 ± 1.25 −1.20 ± 1.15 NS
BMI SDS 0.63 ± 1.07 0.35 ± 0.97 0.35 ± 1.06 0.37 ± 1.13 0.48 ± 1.08 0.34 ± 0.95 NS
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pretreatment height, TS girls born before 1980 were included for 
analyses regarding BL/BW and pretreatment height at 8  years 
(unless they started recombinant GH before 1985). To analyze 
trends in age at the start of GH therapy, TS girls born before 1980 
were excluded (as the approval of TS as an indication for GH 
therapy occurred beyond this birth cohort and this group, by 
definition, was relatively old at the start of GH). For this analysis, 
we also excluded the last group born between 2000 and 2004 as 
their maximum age was only 11 years old in 2012 when KIGS data 
collection ended. Data included in statistical analysis of trends are 
shaded gray in Tables 2 and 3.
We divided data in three categories:
 (a) Displayed and tested (presented as shaded data in Tables 2 
and 3).
 (b) Displayed but not tested (Ht and age), since these data are rel-
evant where sufficient data are available but are likely prone 
to bias. Thus, data are displayed as they are still informative 
but are not tested.
 (c) Not displayed and not tested (puberty), since only insuf-
ficient data are available.
Since age at the start of GH treatment changed over time, we 
additionally compared subgroups from each cohort who had pre-
treatment measurements at a comparable age of 8 years (between 
7.0 and 9.0 years; cohort 1b). Mean exact age at this measurement 
did not differ across the birth year groups.
Cohort 2 was used to assess trends in puberty timing. It 
included only those TS subjects with data during the age 
period when puberty was expected to occur. Therefore, we 
excluded the last group born between 2000 and 2004 as their 
maximum age was only 11 years old in 2012 when KIGS data 
collection ended.
auxological Methods
Height was converted to SDS using both the height reference 
for healthy children of Prader (20) and the reference for TS of 
Ranke et al. (21). To calculate weight SDS, the normal population 
reference of Freeman et al. was used (22). To calculate body mass 
index SDS, the normal population reference of Cole was used 
(23). BW and BL for gestational age SDS were calculated using 
the reference of Niklasson et al. (24). The midparental height SDS 
was calculated as follows: (father’s height SDS + mother’s height 
SDS)/1.61 (25).
Definitions
The onset of puberty was defined by the visit at which either 
spontaneous breast development (Tanner stage >  B1) was first 
observed or the date at which estrogen replacement therapy 
was initiated. The assessment of the qualitative and quantitative 
aspects of estrogen replacement was done by the treating physi-
cians. Furthermore, available data were stratified into whether 
pubertal development started spontaneously or was pharmaco-
logically induced. The group with spontaneous start of puberty 
included patients with spontaneous progression of puberty until 
menarche as well as those who later required sex steroid substitu-
tion before menarche.
statistical analysis
Statistical analyses [descriptive data analysis, calculation of 
SDS, and analysis of variance (ANOVA)] were carried out using 
SAS software (SAS Version 9.2, SAS Institute, Cary NC, USA). 
ANOVA models, F-tests, were applied to determine if there are 
any statistical mean differences between the groups based on year 
of birth. A p-value < 0.05 was considered to indicate statistical 
significance.
TaBle 3 | Secular trends on pubertal timing (mean ± SD).
Birth year Before 1980 1980–1984 1985–1989 1990–1994 1995–1999 2000–2004 p-Value
at puberty start (cohort #2; all patients)
N = [birth weight(BW)/birth length (BL)] 401 536 652 487 136
Age 14.39 ± 2.09 13.44 ± 2.02 13.37 ± 1.62 13.00 ± 1.81 12.42 ± 1.29 <0.001
Height SD score (SDS) (Prader) −2.34 ± 0.98 −1.86 ± 1.04 −1.57 ± 0.92 −1.44 ± 0.90 −1.25 ± 0.99 <0.001
Height SDS (Ranke) 0.68 ± 1.21 1.28 ± 1.29 1.62 ± 1.19 1.81 ± 1.16 2.06 ± 1.30 <0.001
Δ Height − MPH SDS −1.72 ± 1.09 −1.39 ± 1.17 −1.15 ± 1.14 −1.07 ± 1.12 −0.95 ± 1.02 <0.001
Weight SDS −1.48 ± 1.32 −1.04 ± 1.40 −0.72 ± 1.27 −0.57 ± 1.32 −0.37 ± 1.19 <0.001
Body mass index (BMI) SDS 0.30 ± 1.08 0.38 ± 1.14 0.54 ± 1.14 0.60 ± 1.15 0.65 ± 1.02 <0.001
Age at menarche 16.05 ± 1.78 15.07 ± 1.79 14.82 ± 1.64 14.27 ± 1.85 13.86 ± 1.24 <0.001
Duration B2 to M1 (years) 1.82 ± 1.57 1.79 ± 1.35 1.93 ± 1.40 1.68 ± 1.68 1.97 ± 2.27 NS
Spontaneous puberty (%) 15 17 22 27 30 <0.001
Karyotype 45, X (%) 52 52 48 46 59 NS
at puberty start (cohort #2; patients with induced puberty)
N =  340 445 509 323 95
Age 14.38 ± 2.05 13.57 ± 1.94 13.66 ± 1.52 13.17 ± 1.46 12.68 ± 1.12 <0.001
Height SDS (Prader) −2.34 ± 1.01 −1.82 ± 0.99 −1.52 ± 0.95 −1.36 ± 0.86 −1.10 ± 0.95 <0.001
Height SDS (Ranke) 0.69 ± 1.24 1.31 ± 1.24 1.69 ± 1.22 1.87 ± 1.16 2.24 ± 1.26 <0.001
Δ Height − MPH SDS −1.80 ± 1.06 −1.37 ± 1.10 −1.18 ± 1.12 −1.06 ± 1.09 −0.92 ± 1.02 <0.001
Weight SDS −1.44 ± 1.32 −1.07 ± 1.37 −0.72 ± 1.30 −0.57 ± 1.27 −0.35 ± 1.19 <0.001
BMI SDS 0.35 ± 1.05 0.35 ± 1.13 0.55 ± 1.14 0.61 ± 1.10 0.62 ± 1.02 0.003
Age at menarche 16.18 ± 1.71 15.33 ± 1.78 15.23 ± 1.55 14.61 ± 1.76 14.34 ± 0.87 <0.001
Duration B2 to M1 (years) 1.75 ± 1.53 1.76 ± 1.34 1.97 ± 1.52 1.52 ± 1.90 2.27 ± 2.65 NS
at puberty start (cohort #2; patients with spontaneous puberty)
N =  61 91 143 119 41
Age 14.45 ± 2.32 12.79 ± 2.31 12.37 ± 1.58 11.63 ± 1.64 11.80 ± 1.46 <0.001
Height SDS (Prader) −2.36 ± 0.81 −2.04 ± 1.27 −1.73 ± 0.77 −1.47 ± 0.93 −1.59 ± 1.03 <0.001
Height SDS (Ranke) 0.63 ± 1.00 1.11 ± 1.48 1.40 ± 1.04 1.78 ± 1.20 1.63 ± 1.33 <0.001
Δ Height − MPH SDS −1.29 ± 1.14 −1.47 ± 1.48 −1.06 ± 1.21 −0.93 ± 1.18 −1.04 ± 1.06 0.01
Weight SDS −1.71 ± 1.29 −0.92 ± 1.54 −0.73 ± 1.18 −0.37 ± 1.34 −0.42 ± 1.19  0.008
BMI SDS −0.00 ± 1.22 0.49 ± 1.22 0.50 ± 1.17 0.68 ± 1.24 0.72 ± 1.03 NS
Age at menarche 15.43 ± 2.04 13.76 ± 1.20 13.55 ± 1.23 13.10 ± 1.47 12.77 ± 1.31 <0.001
Duration B2 to M1 (years) 2.19 ± 1.75 1.89 ± 1.38 1.81 ± 0.98 2.05 ± 1.23 1.36 ± 1.08 NS
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resUlTs
Birth Parameters, auxological 
Development, and gh Treatment
Distribution of BW and BL of all TS patients in whom 
birth parameters were available (n =  6372) are described in 
Table  1. Throughout the birth year cohorts “before 1980” 
until “1990–1994”, we observed a small ST for BW SDS with 
subsequent stabilization, with an increase of 0.18 SD over time, 
corresponding to about 157–180  g (depending on the gesta-
tional age; Table 2). In addition, a positive ST was observed in 
midparental height SDS.
Height SDS at the start of GH therapy at the standardized 
age of 8  years (range between 7.0 and 9.0  years, see Methods) 
showed a positive ST between before 1980 and 2000–2004, for 
both Prader and Ranke height SDS statistics (Table 2) (Figure 1 
for Ranke height SDS results). In addition, positive STs for height 
SDS (Prader and Ranke height SDS statistics) could also be 
observed both at the start of GH therapy (Table  2) and at the 
start of puberty (thelarche) (Table 3). Comparable to the ST in 
height SDS at 8 years of age, an ST in midparental height was also 
observed (+0.5 SD).
Age at the start of GH therapy declined substantially, from 
10.8 years in the birth cohort 1980–1984 to 7.4 years in the birth 
cohort from 1995 to 1999. As described in Section “Methods”, 
the even more extreme mean ages at the start of GH in the 
before 1980 and 2000–2004 cohorts are likely artifactual, due 
to selection biases.
Pubertal Development
Age at the start of puberty (whether induced or spontaneous) 
declined from 14.4  years in the before 1980 birth cohort to 
12.4 years in the 1995–1999 cohort (p < 0.001). When stratified 
by spontaneous or induced puberty, STs toward an earlier start of 
puberty were evident in both subgroups, and the proportion with 
spontaneous puberty onset increased from 15% in those born 
before 1980 to 30% in those born 1995–1999 (Table 3).
To determine whether age at spontaneous puberty and age at 
the start of GH in patients with TS are associated, we performed 
a correlation analysis, revealing a highly significant correlation 
between age at the start of GH treatment and age at pubertal onset 
[correlation coefficient 0.65 (p-value < 0.0001)], which explained 
32% of the variability in spontaneous puberty with age at GH start 
[intercept = 10.3 years (p < 0.0001), slope = 0.31 (p < 0.0001)].
FigUre 2 | Secular trends on age at menarche in girls with Turner 
syndrome.
FigUre 1 | Secular trends on height in 8-year-old girls with Turner 
syndrome, height SD score (Ranke).
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Age at menarche also declined substantially from 16.0 to 
13.9  years (p <  0.001). Again, this observation remained sig-
nificant in the two subgroups with either spontaneous or induced 
puberty (Table 3; Figure 2).
DiscUssiOn
To the best of our knowledge, this is the first study analyzing 
whether TS girls display the same STs for auxological and puber-
tal development as those observed in the normal population. We 
found a highly significant ST for height at 8 years of age (+0.7 
SDS). In addition, STs for height were present at the start of GH 
treatment and at the start of puberty. However, for these latter 
time points, the mean age differed greatly between the birth 
year groups, limiting direct comparisons. At the age of 8 years—
before either the start of sex steroids or GH treatment may have 
influenced growth—the TS girls born after 2004 were more than 
half an SD taller compared to those born before 1980. Reported 
STs in height in normal populations differ between countries. 
Eastern and developing countries still show marked positive STs 
(26, 27), while conversely Western countries show only small 
(28) or even negative STs in growth (29). In contrast, our large 
group of TS girls included a wide variety of ethnicities, yet the 
positive ST in height SDS at the age of 8  years was observed 
for all, irrespective from their country of residence (data not 
shown). The remarkable positive ST of more than half an SDS, 
which corresponds to about 3 cm gain in height even without 
any endocrine treatment, surpasses contemporary estimates in 
the normal population. A height gain of 0.5 cm/decade or less 
would be expected for the corresponding birth year cohorts in 
most Western countries (30). Thus, the TS girls in this study 
born between 1975 and 2004 exhibited the same degree of ST 
on height at age 8 years as was observed one generation earlier 
in their parents.
It is important to notice that this positive ST in height could 
result in a delay of diagnosis because TS patients at the age of 
eight are nowadays nearly in the normal range or “less short.” 
However, our data show a constant shift toward an earlier start in 
GH treatment (reflecting probably the age of diagnosis) between 
the before 1980 and the post-2000 birth cohorts. Thus, although 
still a significant number of TS subjects seem to be diagnosed late, 
the awareness of TS seems to have improved despite less apparent 
phenotypical features.
We found a small positive ST for BW (+0.18 SD), but only 
a minor variation in BL. These findings are in line with data on 
healthy term infants who show a ST only for BW but not for BL. 
Comparison of recent growth curves and birth parameters (1, 24, 
31) with historical data (2) showed a higher average BW for infants 
born at term. In contrast to that, BL remained constant in almost 
all the industrialized Western countries, and no change in this vari-
able has been detected over the last 40 years. Higher maternal body 
weight and pregnancy weight gain (32) in recent years may be a 
reason for the observed gain in BW. Since both maternal and pater-
nal genes contribute to infants’ birth parameters, the observed ST 
in midparental height might contribute to the observed changes in 
birth parameters. Furthermore, the ST in maternal height might be 
associated with alterations of the intrauterine environment, which 
again could be linked to the observed ST in birth parameters.
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In recent years, epidemiological data from USA (33) and 
Denmark (8) showed STs toward earlier start of puberty in girls. 
We therefore were interested whether the same trend could be 
detected in TS patients in whom spontaneous puberty can be 
observed in about one third. We found a comparable decline in 
the age at spontaneous thelarche of about 2 years between those 
born before 1980 to those born in 2000–2004. As the time interval 
between visits was usually 6 months, the correct age at thelarche 
was likely earlier than that which we recorded. However, this 
limitation applied similarly for each of the five birth year groups 
with no expectation of bias.
The reasons behind the earlier spontaneous thelarche in 
TS subjects are unclear. We initially hypothesized that a lower 
threshold to karyotyping and a broader access to modern 
genetic diagnostics might have led to an increased proportion 
of patients with mosaicism, thereby explaining the doubling in 
the prevalence of spontaneous puberty and the decline in age 
at thelarche. However, as depicted in Table 3, the prevalence of 
patients with monosomy X did not change across the birth year 
groups. As in healthy girls, one can speculate that the increase 
in weight SDS of about one SD in the TS girls with spontaneous 
thelarche might have influenced the age at thelarche. However, in 
other settings the increase in weight did not fully explain the ST 
on puberty in healthy Danish girls (8, 34). Aksglaede and cow-
orkers suggested that factors other than weight, such as changes 
in living conditions, nutrition during fetal development and 
childhood, and the wide distribution of endocrine disrupting 
chemicals (EDCs) (8, 35) might provoke the observed secular 
change. Probably, TS girls are exposed to the same changes in 
environmental con ditions. Therefore, if EDCs are really causally 
related to the reported pubertal changes, these might also be 
related to the even more pronounced decrease in thelarche in 
TS girls.
As already reported in patients with idiopathic GH defi-
ciency, age at puberty start correlated with age at the start of 
GH treatment in our study (36). Although the highly significant 
correlation between age at commencement of GH treatment 
and onset of spontaneous puberty is only an association and 
not proof of a causal relation, one can speculate that exposure to 
elevated GH concentrations might affect gonadotroph function, 
either through a direct or indirect effect (e.g., mediated by IGF-
I). In this context, several in  vitro studies have demonstrated 
that IGF-I is able to directly stimulate gonadotropin synthesis 
and secretion (37), so that a GH-induced increase in circulat-
ing IGF-I levels might contribute to the observed decline in age 
at the start of puberty. However, in a previous study in Italian 
TS patients, neither age at start nor prevalence of spontaneous 
puberty differed between GH-treated patients and a small non-
GH treated control group who received androgen treatment 
(18). Furthermore, in our study, age at the start of GH treatment 
explains only 32% of the observed variability in spontaneous 
puberty, indicating that additional factors are probably involved 
in the physiology of earlier age at start and increased prevalence 
of spontaneous puberty.
The age at pharmacological induction of puberty decreased 
comparably to the age at spontaneous start of puberty. This 
phenomenon might be explained in particular by two factors: 
first, the decrease in age at the start of GH therapy (and prob-
ably age at diagnosis) might allow puberty induction at a more 
physiological age range. Second, the awareness of physicians 
for the psychosocial and physical sequelae of delayed puberty 
induction might have improved over time. In this context, one 
study has reported an even more improved height outcome for 
the early use of very low-dose estrogens in TS girls (38), and 
another study reported no significant influence of early start 
of low-dose estrogens on height development in TS girls (39). 
Together with the negative impact on bone health due to late 
estrogen exposure, these data argue strongly against a delay 
and in favor of an earlier starting age of puberty induction.
Although a ST in thelarche is found in several populations, 
all recent epidemiological studies (40) showed that the timing 
of menarche remained mostly unchanged with a consecutively 
longer interval between thelarche to menarche. In this study, 
we observed a significant reduction in age at menarche, both in 
TS girls with spontaneous as well as in those induced puberty. 
Whereas in TS girls with induced puberty probably the same 
explanations as for earlier age at thelarche might lead to the 
decrease in age at menarche, the reasons for the decrease in 
age at menarche in TS girls with spontaneous puberty remain 
unclear. Since the group with spontaneous start of puberty 
included subjects with spontaneous start but later requirement 
of sex steroid substitution before menarche, we speculate that 
the earlier menarche in this group is related to earlier sex steroid 
replacement therapy, comparable to the earlier start of pharma-
cologically induced puberty.
A major strength of this study is the unprecedented large study 
sample of girls with TS, allowing a comparison of growth and 
pubertal development over time in still sufficiently sized birth 
year cohorts. However, data from post-marketing studies such 
as KIGS have some important shortcomings. Therefore, the data-
base contains no data from untreated TS subjects, which would 
allow determining whether the STs at birth, age 8 years or at the 
start of GH treatment translate to differences in adult height. 
Furthermore, several authors have speculated on the influence of 
socioeconomic factors as causative factors for the STs on height, 
which are not available in the database. Interobserver differences 
in a multicenter database in determining height and pubertal 
status are a potential weakness, but are probably balanced out by 
the large cohort size.
In summary, we find that trends toward increased childhood 
height and earlier pubertal onset operate not only in normal 
populations, but also in TS subjects, who also showed a doubling 
in the prevalence in spontaneous puberty onset between before 
1980 to 1995–1999. In addition to these environment-related 
trends, awareness for TS seems to have improved, leading to 
earlier ages at the start of GH and pharmacological induction of 
puberty.
eThics sTaTeMenT
The patients studied had received recombinant GH (Genotropin®, 
Pfizer Inc.) as part of the pharmacoepidemiologic survey known 
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as KIGS® (Pfizer International Growth Database). KIGS was 
established in 1987 as a worldwide observational registry to 
monitor outcomes and safety of Genotropin (somatropin, Pfizer 
Inc., New York, NY, USA) treatment in children with short 
stature. The KIGS survey was conducted in accordance with the 
Declaration of Helsinki.
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